Literature DB >> 3897043

Insulin and blood pressure in obesity.

C P Lucas, J A Estigarribia, L L Darga, G M Reaven.   

Abstract

To assess factors in overweight persons that account for a tendency toward hypertension, 33 very obese women, 26 to 77 years of age, were studied. Blood pressures in these 33 women varied from low normal to mildly hypertensive. None of them had taken medication for high blood pressure, and none had diabetes mellitus. The effect of independent variables--age, body mass index (weight/height2), fasting serum glucose levels, fasting serum insulin levels, and 24-hour urinary sodium excretion--on systolic and diastolic blood pressure was assessed. There was no correlation between sodium excretion and blood pressure. Age did not correlate with diastolic blood pressure but did correlate with systolic blood pressure when body mass index, serum glucose level, and insulin level were controlled. Diastolic blood pressure correlated with body mass index and serum glucose level, but only the latter remained significant when all independent variables were considered together. Both systolic and diastolic blood pressure were found to be significantly related to fasting serum insulin level (r = 0.47, p = 0.005 and r = 0.68, p less than 0.001) even when age, weight, and serum glucose level were controlled (r = 0.41, p = 0.025 and r = 0.62, p less than 0.001 respectively). The relation between serum insulin and blood pressure was more pronounced in those women with a family history of hypertension. These data indicate that insulin may play a major role in the regulation of blood pressure in obesity and that the previously accepted relation of weight to blood pressure may depend on blood levels of insulin.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3897043     DOI: 10.1161/01.hyp.7.5.702

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  26 in total

1.  Potassium and magnesium in essential hypertension.

Authors:  P S Patki; G S Gokhale; J Singh; D S Shrotri; B Patwardhan
Journal:  BMJ       Date:  1990-12-01

2.  Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans.

Authors:  E A Anderson; R P Hoffman; T W Balon; C A Sinkey; A L Mark
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

3.  Insulin resistance: Is it time for primary prevention?

Authors:  Valentina Mercurio; Guido Carlomagno; Valeria Fazio; Serafino Fazio
Journal:  World J Cardiol       Date:  2012-01-26

4.  Hypertension and non-insulin dependent diabetes.

Authors:  J S Yudkin
Journal:  BMJ       Date:  1991-09-28

Review 5.  Body fat and sympathetic nerve activity.

Authors:  U Scherrer; R Owlya; M Lepori
Journal:  Cardiovasc Drugs Ther       Date:  1996-06       Impact factor: 3.727

6.  Influence of salt on glycaemic response to carbohydrate loading.

Authors:  R O Gans; R J Heine; A J Donker; E A van der Veen
Journal:  Br Med J (Clin Res Ed)       Date:  1987-05-16

7.  Elevated serum uric acid--a facet of hyperinsulinaemia.

Authors:  M Modan; H Halkin; A Karasik; A Lusky
Journal:  Diabetologia       Date:  1987-09       Impact factor: 10.122

8.  Hyperinsulinemia in hypertension: increased secretion, reduced clearance or both?

Authors:  D Giugliano; A Quatraro; A Minei; N De Rosa; L Coppola; F D'Onofrio
Journal:  J Endocrinol Invest       Date:  1993-05       Impact factor: 4.256

9.  Increasing peripheral insulin sensitivity by protein tyrosine phosphatase 1B deletion improves control of blood pressure in obesity.

Authors:  Eric J Belin de Chantemèle; Mohammed Irfan Ali; James D Mintz; William E Rainey; Michel L Tremblay; David J Fulton; David W Stepp
Journal:  Hypertension       Date:  2012-10-08       Impact factor: 10.190

10.  Insulin attenuates vasopressin-induced calcium transients and a voltage-dependent calcium response in rat vascular smooth muscle cells.

Authors:  P R Standley; F Zhang; J L Ram; M B Zemel; J R Sowers
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.